Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Polyrizon Ltd. ( (PLRZ) ) has shared an announcement.
On June 11, 2025, Polyrizon Ltd. announced promising preclinical results from a study on its hydrogel-based Trap & Target (T&T) platform, conducted with the University of Parma. The study demonstrated successful intranasal delivery of the hydrogel formulation to the upper nasal cavity, crucial for central nervous system (CNS) drug delivery. This targeted delivery is particularly promising for conditions requiring rapid brain access, such as opioid overdose and epileptic seizures. The results validate the T&T technology’s potential in developing therapies for acute neurological and psychiatric conditions, supporting further preclinical development and safety studies.
More about Polyrizon Ltd.
Polyrizon Ltd. is a biotechnology company specializing in the development of innovative medical device hydrogels delivered as nasal sprays. These hydrogels form a protective barrier in the nasal cavity, potentially shielding against viruses and allergens. The company is advancing its proprietary Capture and Contain (C&C) hydrogel technology for intranasal drug delivery and is also developing the Trap and Target (T&T) platform for nasal delivery of active pharmaceutical ingredients.
Average Trading Volume: 1,785,900
Technical Sentiment Signal: Strong Sell
Current Market Cap: $4.31M
Learn more about PLRZ stock on TipRanks’ Stock Analysis page.